Markets

Sector Update: Health Stocks Generally Flat Pre-Bell

Top Health-care stocks:

JNJ: +0.16%

PFE: +0.17%

ABT: flat

MRK: flat

AMGN: flat

Health-care shares were generally flat in pre-market trade Thursday.

In health-care stocks news, BioScrip ( BIOS ), a provider of infusion and home care management solutions, announced a wider loss per share than the same period a year ago and revenues that beat Street expectations.

The company reported a Q3 adjusted loss per share of $0.42, wider than the loss of $0.02 a year ago and missing analyst estimates of $0.02 in earnings for the quarter, if comparable.

Total revenues of $243.95 million were up from $190.63 million in Q3 2013 but beat analyst projections of $242.8 million.

Shares in the company were trading 8.33% lower at $5.72 during Thursday's pre-market trading session. Over the past 52 weeks, the company has traded between $5.59 and $9.05.

Meanwhile, PhotoMedex ( PHMD ) shares were lower in recent pre-market trade after reporting a larger loss in Q3 than had been predicted by the Street and as its revenue fell short of the consensus.

The provider of integrated disease management and aesthetic solutions said it reported a non-GAAP loss of $0.27 in the quarter, down from a profit of $0.11 a year ago and compared to the $0.23 loss expected by analysts polled by Capital IQ.

Revenue rose 17% to $53.7 million while the Street had expected $60.8 million.

Shares in the company were trading 19.09% lower at $2.67 during Thursday's pre-market trading session. Over the past 52 weeks, the company has traded between $2.52 and $16.82.

Meanwhile, Horizon Pharma ( HZNP ) shares were higher in recent pre-market trade after reporting Q3 earnings that exceeded analysts' estimates and as it raised its guidance for 2014.

The biopharmaceutical company said adjusted net income was $0.24 per diluted share compared to a loss of $0.03 a year ago and better than the $0.14 average estimate from analysts polled by Capital IQ.

Revenue more than tripled to $75.1 million from $24.1 million compared to the $73.7 million consensus estimate.

Shares in the company were trading 6.80% higher at $13.20 during Thursday's pre-market trading session. Over the past 52 weeks, the company has traded between $3.70 and $18.30.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

HZNP BIOS

Other Topics

Commodities